Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones

被引:77
|
作者
Winski, SL
Swann, E
Hargreaves, RHJ
Dehn, DL
Butler, J
Moody, CJ
Ross, D
机构
[1] Univ Colorado, Sch Pharm, Dept Pharmaceut Sci, Hlth Sci Ctr, Denver, CO 80262 USA
[2] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
[3] Univ Exeter, Exeter, Devon, England
[4] Christie Res Ctr, Manchester, Lancs, England
[5] Univ Salford, Dept Biol Sci, Salford M5 4WT, Lancs, England
关键词
NQO1; antitumor quinones; enzyme-directed drug development; preclinical research; in vitro testing;
D O I
10.1016/S0006-2952(01)00631-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To investigate the importance of NAD(P)H:quinone oxidoreductase 1 (or DT-diaphorase; NQO1) in the bioactivation of antitumor quinones, we established a series of stably transfected cell lines derived from BE human colon adenocarcinoma cells. BE cells have no NQO1 activity due to a genetic polymorphism. The new cell lines, BE-NQ, stably express wild-type NQO1. BE-NQ7 cells expressed the highest level of NQO1 and were more susceptible [determined by the thiazolyl blue (MTT) assay] to known antitumor quinones and newer clinical candidates. Inhibition of NQO1 by pretreatment with an irreversible inhibitor, ES936 [5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione], protected BE-NQ7 cells from toxicity induced by streptonigrin, ES921 [5-(aziridin-1-yl)-3-(hydroxymethyl)-1,2-dimethylindole-4,7-dione], and RH1 [2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-benzoquinone]. RH1 was evaluated further by clonogenic assay for cytotoxic response and was more cytotoxic to BE-NQ7 cells than to BE cells. Cytotoxicity was abrogated by inhibition of NQO1 with ES936 pretreatment. Using a comet assay to evaluate DNA cross-linking, BE-NQ7 cells demonstrated significantly higher DNA cross-links than did BE cells in response to RH1 treatment. DNA cross-linking in BE-NQ7 cells was observed at very low concentrations of RH1 (5 nM), confirming that NQO1 activates RH1 to a potent cross-linking species. Further studies using streptonigrin, ES921, and RH1 were undertaken to analyze the relationship between NQO1 activity and quinone toxicity. Toxicity of these compounds was measured in a panel of BE-NQ cells expressing a range of NQO1 activity (23-433 nmol/min/mg). Data obtained suggest a threshold for NQO1-induced toxicity above 23 nmol/min/mg and a sharp dose-response curve between the no effect level of NQO1 (23 nmol/min/mg) and the maximal effect level (> 77 nmol/min/mg). These data provide evidence that NQO1 can bioactivate antitumor quinones in this system and suggest that a threshold level of NQO1 activity is required to initiate toxic events. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1509 / 1516
页数:8
相关论文
共 50 条
  • [1] Relationship between NAD(P)H:quinone oxidoreductase 1 (NQO1) levels in a series of stably transfected cell lines and susceptibility to antitumor quinones.
    Winski, SL
    Swann, E
    Hargreaves, E
    Robert, HJ
    Butler, J
    Moody, CJ
    Ross, D
    CLINICAL CANCER RESEARCH, 1999, 5 : 3765S - 3766S
  • [2] NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones
    Siegel, David
    Yan, Chao
    Ross, David
    BIOCHEMICAL PHARMACOLOGY, 2012, 83 (08) : 1033 - 1040
  • [3] Overexpression of NAD(P)H: quinone oxidoreductase 1 (NQO1) and genomic gain of the NQO1 locus modulates breast cancer cell sensitivity to quinones
    Glorieux, Christophe
    Sandoval, Juan Marcelo
    Dejeans, Nicolas
    Ameye, Genevieve
    Poirel, Helene Antoine
    Verrax, Julien
    Buc Calderon, Pedro
    LIFE SCIENCES, 2016, 145 : 57 - 65
  • [4] Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1)
    Megarity, Clare F.
    Benley, Hoda Abdel-Aal
    Caraher, M. Clare
    Scott, Katherine A.
    Whitehead, Roger C.
    Jowitt, Thomas A.
    Gutierrez, Aldo
    Bryce, Richard A.
    Nolan, Karen A.
    Stratford, Ian J.
    Timson, David J.
    CHEMBIOCHEM, 2019, 20 (22) : 2841 - 2849
  • [5] A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): Relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity
    Ross, D
    Traver, RD
    Siegel, D
    Kuehl, BL
    Misra, V
    Rauth, AM
    BRITISH JOURNAL OF CANCER, 1996, 74 (06) : 995 - 996
  • [6] NAD(P)H:quinone oxidoreductase (NQO1) loss of function in Burkitt's lymphoma cell lines
    Bruge, Francesca
    Virgili, Samantha
    Cacciamani, Tiziana
    Principi, Federica
    Tiano, Luca
    Littarru, Gian Paolo
    BIOFACTORS, 2008, 32 (1-4) : 71 - 81
  • [7] NAD(P)H:quinone oxidoreductase 1 (NQO1):: Role as a superoxide scavenger
    Siegel, D
    Gustafson, D
    Dehn, D
    Boonchoong, P
    Han, JY
    Berliner, L
    Ross, D
    FREE RADICAL BIOLOGY AND MEDICINE, 2003, 35 : S14 - S14
  • [8] Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues
    Sieger, D
    Ross, D
    FREE RADICAL BIOLOGY AND MEDICINE, 2000, 29 (3-4) : 246 - 253
  • [9] Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer
    Lewis, AM
    Ough, M
    Hinkhouse, MM
    Tsao, MS
    Oberley, LW
    Cullen, JJ
    MOLECULAR CARCINOGENESIS, 2005, 43 (04) : 215 - 224
  • [10] NAD(P)H: quinone oxidoreductase (NQO1) gene polymorphism and schizophrenia
    Hori, H
    Ohmori, O
    Matsumoto, C
    Shinkai, T
    Nakamura, J
    PSYCHIATRY RESEARCH, 2003, 118 (03) : 235 - 239